JW (Cayman) Therapeutics Co. Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JWCTF research report →
Companywww.jwtherapeutics.com
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer.
- CEO
- Min Liu
- IPO
- 2021
- Employees
- 281
- HQ
- Shanghai, CN
Price Chart
Valuation
- Market Cap
- $116.65M
- P/E
- -1.35
- P/S
- 2.65
- P/B
- 1.34
- EV/EBITDA
- -2.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 43.15%
- Op Margin
- -105.50%
- Net Margin
- -196.12%
- ROE
- -75.15%
- ROIC
- -36.15%
Growth & Income
- Revenue
- $276.33M · 74.65%
- Net Income
- $-540,962,213 · 8.41%
- EPS
- $-1.33 · 6.99%
- Op Income
- $-241,728,741
- FCF YoY
- 77.51%
Performance & Tape
- 52W High
- $0.66
- 52W Low
- $0.16
- 50D MA
- $0.29
- 200D MA
- $0.41
- Beta
- 1.91
- Avg Volume
- 4.42K
Get TickerSpark's AI analysis on JWCTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our JWCTF Coverage
We haven't published any research on JWCTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JWCTF Report →